Effects of differences in polymorphism of gene encoding enzyme faenesyl diphosphate synthase (FDPS), rs2297480, on bone mineral density and biochemical markers of bone turnover in thai postmenopausal women

Journal of the Medical Association of Thailand

Volumn 94, Issue 10 SUPPL., 2011, Pages

  Songpatanasilp, Thawee ^a   Chanprasertyothin, Suwannee ^b  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Bisphosphonates; Bone mineral density; Bone turnover markers; FDPS gene; rs2997480

Indexed keywords

BETA CARBOXY TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; INTACT PARATHYROID HORMONE; N MID OSTEOCALCIN; OSTEOCALCIN; PARATHYROID HORMONE; UNCLASSIFIED DRUG; GERANYLTRANSFERASE;

ADULT; AGED; ARTICLE; ASIAN; BONE DENSITY; BONE TURNOVER; CAUCASIAN; CHEMICAL ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ETHNIC DIFFERENCE; FARNESYL DIPHOSPHATE SYNTHASE GENE; FEMALE; FEMUR NECK; GENE; GENE FREQUENCY; GENOTYPE; HIP; HUMAN; LUMBAR SPINE; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PROSPECTIVE STUDY; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; T SCORE; THAI; BONE REMODELING; GENETICS; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; THAILAND;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE REMODELING; FEMALE; GERANYLTRANSTRANSFERASE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; THAILAND;

EID: 84858034938     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
2. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-10.
3. Taechakraichana N, Angkawanich P, Panyakhamlerd K, Limpaphayom K. Postmenopausal osteoporosis: what is the real magnitude of the problem in the Thai population? J Med Assoc Thai 1998; 81: 397-401.
4. Phadungkiat S, Chariyalertsak S, Rajatanavin R, Chiengthong K, Suriyawongpaisal P, Woratanarat P. Incidence of hip fracture in Chiang Mai. J Med Assoc Thai 2002; 85: 565-71.
5. Chariyalertsak S, Suriyawongpisal P, Thakkinstain A. Mortality after hip fractures in Thailand. Int Orthop 2001; 25: 294-7.
6. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81: 646-56.
7. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285-9.
8. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22: 15-28.
9. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
10. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-80.
11. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31: 620-5.
12. Recker RR, Weinstein RS, Chesnut CH 3rd, Schimmer RC, Mahoney P, Hughes C, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004; 15: 231-7.
13. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6.
14. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92.
15. Ho AY, Kung AW. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 2005; 39: 1428-33.
16. Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004; 11: 405-15.
17. Iwamoto J, Takeda T, Sato Y, Uzawa M. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei Med J 2004; 45: 676-82.
18. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
19. Cauley J, Black D, Boonen S, Cummings S, Delmas P, Eastell R. Effect of zoledronic acid 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: results from HORIZON-PFT. [abstract]. Osteoporosis Int 2007; 18 (Suppl 1): S26.
20. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371: 1-12.
21. Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996; 11: 1841-9.
22. Kobayashi N, Fujino T, Shirogane T, Furuta I, Kobamatsu Y, Yaegashi M, et al. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 2002; 41: 193-201.
23. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTPbinding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9.
24. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235-42.
25. Levy ME, Parker RA, Ferrell RE, Zmuda JM, Greenspan SL. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 2007; 57: 247-52.
26. Wahner HW, Steiger P, Stetten EV. Instruments and measurement techniques. In: Wahner HW, Fogelman I, editors. The evaluation of osteoporosis: dual energy x-ray absorptiometry in clinical practice. London: Martin Dunitz; 1994: 14-34.
27. Schmidt-Gayk H, Spanuth E, Kotting J, Bartl R, Felsenberg D, Pfeilschifter J, et al. Performance evaluation of automated assays for beta- CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 2004; 42: 90-5.
28. Eastell R, Baumann M, Hoyle NR, Wieczorek L. Bone markers: biochemical and clinical perspectives. London: Martin Dunitz; 2001.
29. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
30. Chen X, Levine L, Kwok PY. Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 1999; 9: 492-8.
31. Dawson-Hughes B, Gold DT, Rodbard HW, Bonner FJ, Khosla S, Swift SS, et al. Physician's guide to prevention and treatment of osteoporosis [database on the Internet]. Washington, DC: National Osteoporosis Foundation; 2003 [cited 2010 Dec 21]. Available from: http://www.nof.org/
32. NCBI. Single nucleotide polymorphism database (dbSNP) on FDPS rs2297480 gene [database on the Internet]. 2010 [cited 2010 Dec 21]. Available from: http://www.ncbi.nlm.nih.gov/snp?term=FDPS%20rs2297480
33. Olmos JM, Zarrabeitia MT, Hernandez JL, Sanudo C, Gonzalez-Macias J, Riancho JA. Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates. Pharmacogenomics J 2010. The Pharmacogenomics Journal advance online publication, 14 December 2010; doi:10.1038/tpj.2010.88.